PPT-How to Maintain Outcomes & Quality in CABG

Clifford W Barlow FRCS DPhil Southampton General Hospital Southampton UK Quality Quality and Outcomes differ for different individuals Are you operating for survival or symptoms Shortterm Survival . Audio: 1-888-469-3145. Passcode. : 2045270. The webinar will begin shortly.. Strengthening Applications: . Quality Review of SOAR Applications. Presented by:. SAMHSA SOAR Technical Assistance Center. Susana G. Garcia MD. No Disclosure. Objectives. Review the current definition, risk factors, clinical impact and incidence of PMI. Describe the different clinical presentation of PMI and how this dictate the goal and approach to diagnosis and treatment of PMI. ECO Advisory Board. March, 2012. DRAFT. Topics. Why identify critical markers of high quality data?. Anticipated use. 3 areas of focus. Draft critical markers. Where these might be discussed in the APR. Sawan. , Bassam . Abou. Khalil.. Faculty of Medicine, University of . Balamand. , Beirut, Lebanon.. Daniel J. Rader.. Perelman School of Medicine, University of Pennsylvania, PA USA.. Very Severe Hypertriglyceridemia Prior to CABG: . The Role of the Voluntary Sector . WSCB. Quality Tools. There are a number of tools WSCB uses to do this:. Multi-agency dataset. Multi-agency audit programme. Report on . Single Agency . audits . Agency Walkabouts. UCSF Transplant QI committee, Chair. UCSF . Dept. of Surgery QI committee. UCSF Clinical performance improvement committee, Chair. UCSF Patient . S. afety . C. ommittee. Former Chair, ASTS Standards and Quality committee. Revascularization in Stable Ischemic Heart Disease. Bobby Mathew, MD. LSU Internal Medicine, HO-II. Definitions. Recommendations for revascularization in the setting of symptomatic, stable ischemic heart disease; does not include revascularization in the setting of acute MI. by Brooke Culclasure, Ph.D.. May 3, 2016. Introductions. Presenter is Dr. Brooke Culclasure, research director in the Riley Institute at Furman University and principal investigator of numerous studies across S.C.. vs.. . c. oronary artery bypass for multi-vessel disease: a meta-analysis. . Nirav C Patel MD, Jonathan M Hemli MD, Karthik Seetharam MD, Annapoorna Uttara BS, Derek R Brinster MD,. . Luigi Pirelli MD, Chad . On behalf of the PRECOMBAT Investigators. Professor of Medicine, University of Ulsan College of Medicine, . Heart Institute, Asan Medical Center, Seoul, Korea . PRECOMBAT Trial. Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using . SocietySurgeons(ANZSCTS)ZealandElsevierrights *CorrespondingauthorMonashCardiovascularResearchCentre,UniversityMonashHeart,Health,adam.brown@monash.edu BackgroundOff-pump coronary artery bypass grafti "",,~~~._-~~~~~~~~ fILE COpy SURGERY ASSURING QUALITY WHILE CONTROLLING MEDICARE COSTS OFFICE OF INSPECTOR GENERAL OFFICE OF ANALYSIS AND INSPECTIONS ':'3 ".......oz..­ I"'E ";t. s;.r". Au lesions. The hazard . was highest . with CABG in the first 30 . days with better outcomes with PCI; between . 30 days and . 5 . years, . outcomes were inferior . with PCI compared with . CABG. CABG. (n = 592). Kappetein. , Joseph F. . Sabik. , Patrick W. . Serruys. and the EXCEL investigators. EXCEL. Five-year Outcomes from a Randomized Trial of PCI vs. CABG in Patients with Left Main Coronary Artery Disease.